Refine by
Brain Cancer Suppliers & Manufacturers
31 companies found
based in, CHINA
Mol Scientific provides customized peptide synthesis services including linear peptides, modified peptides, protein cross-linked peptides and more. Mol Scientific is a national high-tech enterprise, committed to providing high quality products and ...
![Mol Scientific - Model MPE0009823 - Deleted in malignant brain tumors 1 protein [2385-2413] peptide](https://d32zuqhgcrpxli.cloudfront.net/eyJidWNrZXQiOiJlZS1maWxlcyIsImtleSI6ImZpbGVzLzEyNzQ2MS9pbWFnZXMvMTI3NDYxXzBfMjAyMjA4MTYwNzQ1MDkxNjk5ODQ1XzQwMC5wbmciLCJlZGl0cyI6eyJyZXNpemUiOnsiZml0IjoiY29udGFpbiIsImJhY2tncm91bmQiOnsiciI6MjU1LCJnIjoyNTUsImIiOjI1NSwiYWxwaGEiOjF9LCJ3aWR0aCI6MTQzLCJoZWlnaHQiOjEwMn19fQ== "Mol Scientific - Model MPE0009823 - Deleted in malignant brain tumors 1 protein [2385-2413] peptide")
Mol Scientific offer high-quality Deleted in malignant brain tumors 1 protein [2385-2413] peptide product(MPE0009823). Mol Scientific committed to bring our esteemed customers high quality products and the finest services at highly competitive ...
based inNew York City, NEW YORK (USA)
Lauren Sciences is a privately-held New York biotechnology company focused on developing its V-Smart platform to create a robust pipeline of V-Smart therapeutics consisting of central nervous system (CNS)-active drugs that normally do not cross the ...
based inBellevue, WASHINGTON (USA)
EMulate Therapeutics is a clinical-stage therapeutic device company utilizing its patented proprietary radio frequency energy (RFE) technology, targeted at the low and ultra-low ends of the RFE spectrum (ulRFE®), to provide safe and effective ...
based inRichmond, BRITISH COLUMBIA (CANADA)
BioMark is an oncology-focused company with advanced near-to- market liquid biopsy diagnostic technologies. Our technology improves patient comfort, outcomes and early cancer detection. Biomark owns various intellectual properties, developed for the ...
based inToronto, ONTARIO (CANADA)
Theralase was one of the first companies in North America to bring CLT to patients and the first company in the world to bring personalized ACT to patients individual tissue characteristics. With our multi-discipline experience in physics, ...
Theralase is laser focused on advancing the cutting-edge Anti-Cancer Therapy (“ACT”) towards commercialization, providing an alternative treatment methodology for Non-Muscle Invasive Bladder Cancer (“NMIBC”) patients ...
based inFoothill Ranch, CALIFORNIA (USA)
TAE Life Sciences (TLS) is a biologically-targeted radiation therapy company focused on developing novel treatments to improve the lives of patients with invasive, recurrent and difficult to treat cancers. Founded in 2017, TLS is the only company ...
TAE Life Sciences is committed to developing a portfolio of novel targeted boron drugs to expand the application of BNCT to other cancer types and to provide even better outcomes for indications historically treated with Boronophenylalanine (BPA), a ...
based inCambridge, MASSACHUSETTS (USA)
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer ...
based inBurton upon Trent, UNITED KINGDOM
The Asbestos Testing and Consultancy Association (ATaC) is the leading trade association in the UK for the asbestos testing and consulting services sector. ATaC has represented the interests of asbestos testing and consultancy specialists for over ...
based inHelsinki, FINLAND
Nexstim was established in 2000 to commercialise the opportunity of adding navigation to an existing transcranial magnetic stimulation (TMS) technology. The founders believed that navigation and making the TMS visible with the help of navigation is ...
Nexstim offers targeted and effective therapies and diagnostics for challenging brain diseases and disorders. Our technology is solidly grounded in scientific and clinical research. We closely collaborate with key opinion leaders who like us, ...
based inBingham, MICHIGAN (USA)
In 2017, a group of internationally-recognized MRI industry professionals and entrepreneurs founded SpinTech, Inc. with the goal of transforming advanced MRI techniques, previously reserved only for the research realm, into practical applications to ...
based inSan Jose, CALIFORNIA (USA)
Our transformative vision for the future of radiation therapy began with the breakthrough development of our miniaturized x-ray source – so small, it could fit on the tip of your finger. Today, this proprietary technology, combined with the ...
The versatile Xoft Axxent Electronic Brachytherapy (eBx) System utilizes state-of-the-art 50kV x-ray technology to provide expanded treatment options for a range of cancers. The Xoft System provides isotope-free HDR therapeutic radiation of the ...
based inBoston, MASSACHUSETTS (USA)
CervoMed is a clinical stage company dedicated to the development and commercialization of drug treatments for neurodegenerative diseases with a focus on the early stages of the neurodegenerative process. Until August 2023, CervoMed was known as ...
based inMinnetonka, MINNESOTA (USA)
Monteris Medical was founded in 1999 with the sole focus to help patients suffering from neurological diseases. The company’s goal remains: to create a minimally invasive surgical option for use in the brain. Monteris is a private equity backed ...
Dependable skull fixation for neurosurgical devices. The only cranial fixation bolt with a robotic interface to enable precise laser delivery. ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Hypocrellin A is a PKC inhibitor that exerts antidiabetic activity by reversing the effects of high glucose on endothelin (ET-1) expression. Hypocrellin A is also a photosensitizer for photodynamic therapy (PDT) with anticancer, antibacterial and ...
based inAarhus C, DENMARK
Cercare Medical is based on +25 years of research in perfusion imaging and artificial intelligence. Our novel biomarkers provide unparalleled patient insights. We are bridging the gap between science and clinical practice. With our amazing ...
based inPasadena, CALIFORNIA (USA)
LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in ...
Pre-clinical studies showed that LB-100 alone inhibits a spectrum of human cancers but when combined with standard cytotoxic drugs and/or radiation, LB-100 potentiates their effectiveness against hematologic and solid tumor cancers without enhancing ...
based inAlmere, NETHERLANDS
We’re proud of what Medstone has achieved so far. We’ve built a platform for pharmacists, we offer artificial intelligence solutions for scientific analyses, and we have our own pharmaceutical wholesale. We do all these things because we have one ...
based inPalo Alto, CALIFORNIA (USA)
Nirmidas Biotech was founded in September of 2013. We are a member of the Janssen Labs (JLABS) and QB3 programs, the Stanford StartX Med Program, and the MIT Industrial Liaison Program (MIT ILP). We are also a StartX Med COVID-19 Task Force Company ...
based inOlathe, KANSAS (USA)
TVAX Biomedical is a clinical stage development company advancing its novel targeted cell-based immunotherapy for the treatment of cancer. TVAX Biomedical is developing a paradigm-shifting cancer treatment that offers the promise of improved ...
TVAX®’s lead candidate (TVI-Brain-1) is being evaluated for the treatment of brain cancer and targets glioblastomas. The drug candidate has received Fast Track Designation by the US Food ...
based inRockville, MARYLAND (USA)
Theriva™ is a clinical-stage immuno-oncology company developing oncolytic viruses intended to overcome the protective barrier surrounding solid tumors and selectively kill tumor cells. Our developmental therapies stem from the laboratory of Dr. ...
Building on the clinical advancement of VCN-01, Theriva developed the Albumin Shield™ technology to protect oncolytic viruses from circulating anti-oncolytic virus antibodies after systemic administration. We anticipate that this technology ...